- Clinical validation of high throughput assay that provides numeric results (titer) of neutralizing antibodies
- Former COVID-19 patients, in a small preliminary sample set, saw marked decline in neutralizing antibodies within six months
- Assay shows no guarantee that severe disease results in higher levels of antibody protection
ROCHESTER, Minn., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Imanis Life Sciences (“Imanis“ or “The Company“), in collaboration with Vyriad, Inc. and Regeneron, today announced data from its latest improved IMMUNO-COVTM test, an assay for the quantitative measure of SARS-CoV-2 (COVID-19) neutralizing antibodies. The manuscript is available on medRxiv and has been submitted for additional publication following scientific peer review.
Data acquired from a small initial cohort showed that neutralizing antibodies declined at least 50% within six months in nearly all individuals recovering from COVID-19 infection. Samples from this small test group were first secured in April and then again in October and tested via IMMUNO-COV, the first scalable, quantitative virus neutralizing antibody test for COVID-19. The results correlated closely with those acquired by plaque reduction neutralization test (PRNT), which remains ...
Full story available on Benzinga.com